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Available online 3 August 2016Many metrics, including metabolic proﬁles, have been used to analyze cell health and optimize productivity. In
this study, we investigated the ability of a lipid supplement to increase protein yield. At a concentration of 1%
(v/v) the lipid supplement caused a signiﬁcant increase in protein titer (1118 ± 65.4 ng 105 cells−1 days−1)
when compared to cultures grown in the absence of supplementation (819.3 ± 38.1 ng 105 cells−1 days−1;
p b 0.05). This equated to a 37% increase in productivity. Furthermore, metabolic proﬁles of ammonia, glutamate,
lactate, and glucose were not signiﬁcantly altered by the polar lipid supplement. In a separate set of experiments,
using the supplement as a feed resulted in 2 notable effects. The ﬁrst was a 25% increase in protein titer. The
second was an extension of peak protein production from 1 day to 2 days. These results suggest that lipid
supplementation is a promising avenue for enhancing protein production. In addition, our results also suggest
that an increase in protein production may not necessarily require a change in the metabolic state of the cells.
© 2016 The Author. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural. on behalf of Research Network of ComputaBiotechnology. This is an open access article under the CC BY license
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Using proteins as therapies was ushered in during the early 1980's
with the introduction of EPO. Since then, the biologics market has
seen a signiﬁcant increase in the number of products and the total
revenue generated each year. The sales of biologics have surpassed
$125 billion [1]. As the market has grown, there has been increased
competition as numerous companies target therapeutics for the same
indication as well as new indications. In addition, biosimilars, already
popular in Europe, are growing rapidly in the United States and else-
where. This creates competitive price pressure and the need for biotech
companies to optimize their protein production processes.
Enhancing protein production of cultured cells is a common goal
throughout the biomanufacturing industry. This commonly consists of
an ongoing process of optimizing cell lines in serum free conditions in
order to balance cell proliferation and protein production.
Serum free media have been optimized based on certain principles.
The original serum free media was made by Ham in the 1960s [2]. It
was based on adding the amino acids, vitamins, and salts needed for
cells to grow. The same concept is generally used as a base media
today but as technology has improved so have the methods of analysis.
Assays testing metabolic byproducts and investigating proteomics areused today to better optimize a media for CHO cell lines [3–7]. The use
rate of amino acids or glucose can be determined to identify the constit-
uents rapidly used during a run andmay need replenishment, usually in
the form of a feed and or feeds. None of these assays screen for lipids or
cholesterol. In fact, the typical metabolic analysis looking at the TCA
cycle would not be able to predict a beneﬁt or show the harm of not
having lipids and cholesterol. It has been reported that essential fats
can be beneﬁcial for cell health and protein production [6,8–10].
Here we investigate the utility of a novel approach to optimization
using Cell-Ess® as a feed or an initial supplement to show proof of
principle of adding lipids to culture. Furthermore Cell-Ess is tested as a
feed supplement and in a small bioreactor as a model for use in large
scale bio-production and use in a single use bioreactor. In this report
we hypothesize that adding lipids will beneﬁt protein production and
then set out a set of experiments to test the hypothesis.
2. Materials and methods
2.1. Cell culture
Suspension Chinese Hamster Ovary (CHO) cells expressing several
different monoclonal antibodies (mAb) frommultiple individual clonestional and Structural Biotechnology. This is an open access article under the CC BY
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ment was administered using a dosing paradigm as indicated for each
experiment. The effect on protein titer and common metabolic proﬁles
were determined and analyzed.
For these experiments two different stably transfected mAb single
isolated CHO cell clones were used. The CHO cells were either grown
in SAFC (Sigma, St. Louis, MO) serum free media or FortiCHO (Thermo
Life). CHO cells were thawed and expanded prior to seeding in shake
ﬂasks.
2.2. Supplement with Cell-Ess
Cellswere seeded in shake ﬂasks. Cell-Esswas given as a supplement
independent of other supplements and in addition to normal feeds at
increasing concentrations. Cell-Ess (Essential Pharma, Ewing, NJ) was
either added at the beginning of culture for protein expression or
added as a feed as indicated.
2.3. Protein analysis
The mAb titers were calculated using two different methods. For the
GS0 cells grown in SAFCmedia the cellswere puriﬁed on a proteinA col-
umn and then quantiﬁed by in a spectrophotometer at a wavelength of
280. The mAb from the DG44 cells grown in FortiCHO were quantiﬁed
by an antibody speciﬁc ELISA.A
C
Fig. 1. IncreasedmAb titer with initial lipid supplement. The addition of Cell-Ess as an initial sup
the ability of the lipids supplement to increasemAb titers over control. In this ﬁgure the increase
is shown as a percent over control. In a similar experiment with addition of lipid at a different
shown as a percent increase over control.2.4. Metabolic analysis
Samples were taken at the indicated time points and frozen. At the
end of the run the samples were thawed and run on the BioProﬁle
Flex analyzer (Nova Biomedical, Waltham, MA).
3. Results
3.1. Addition of Cell-Ess® as a supplement signiﬁcantly increases titer
Large-scale protein production has predominantly moved to serum
free systems developed for CHO cell lines. Serum free media systems
are made by multiple companies in the life science industry, like Ther-
mo Fisher Scientiﬁc, one of the industry leaders. Thermo provides sever-
al brands of CHO cell media including but not limited to FortiCHO and
OptiCHO. In theory the completemedia systems are ready for use. Inter-
estingly, even though there are readily available products, many
biomanufacturers will make internal modiﬁcations to optimize protein
production for a speciﬁc cell line suggesting genetic differenceswere in-
troduced to each CHO cell clone. In this study we investigated if the ad-
dition of a lipid supplement, Cell-Ess®, would lead to an increase in
protein production across different clones in two different genetic back-
grounds. A multi-step approach was utilized where proof of principle
was researched to test the hypothesis of the beneﬁt of adding lipids in
a simpliﬁed controlled model. The second step was to test a complex
model for fed batch in shake ﬂasks where there are multiple variables.B
plement in a short 7 day culture model was done inmultiplemedia systems investigating
in titer due to the addition of Cell-Ess to SAFCmedia is shown in 1A and in 1B the increase
site with a different CHO clone the cells were grown in the Thermo media, Forti-CHO and
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Fig. 2. Viable cell density in mAb producing CHO cells with lipid supplement. Cell-Ess was added at increasing amounts in two independent experiments done with two different stably
transfected CHO cell clones. In SAFC SFM (A) 5% Cell-Ess reduced growth while in FortiCHO media (B) 5% Cell-Ess had a similar growth pattern to control.
321A. Elhofy / Computational and Structural Biotechnology Journal 14 (2016) 319–324The last part of the investigation was the addition of lipids to a scalable
small bioreactor utilizing a single use bioreactor (SUB)where lipid addi-
tives previously.
The ﬁrst study on proof of principle was designed to be open-ended
allowing for a variety of outcomes. Four theoretical outcomes were
possible; an advantage of using the lipid supplement at a deﬁned
percentage; an advantage of using Cell-Ess regardless of percentage of
supplement used; the addition of the lipid supplement provided no ef-
fect; and lastly Cell-Ess ® would have a negative effect on protein titer.
Asmentioned previously, there aremultiplemanufacturers of serum
free media where variability in performance has been observed. In an
effort to understand how Cell-Ess ® can affect titer, we measured Cell-
Ess's effect on titer output in two independent systems. One system uti-
lized a clone designed for use speciﬁcally with FortiCHO and another
clone was designed to produce speciﬁcally in Sigma's media. In a
shake ﬂask study the lipid supplement was added once at the
initiation of culture. A range of Cell-Ess® was added to the shake ﬂasks
starting at 0.5%, up to 15%. We found there was a signiﬁcant increase in
monoclonal antibody productionwith the addition of 1% Cell-Ess ® (see
Fig. 1). There was a statistically signiﬁcant increase in titer at 1%,
increasing output from 126 μgrams/ml to 143 μgrams/ml, a 25% increase
using the SAFCmedia (see 1a and 1b). Similarly, the addition of the lipids
to LifeTech's FortiCHOmedia(Fig. 1C) resulted in a similar and signiﬁcant
increase in titer. Interestingly, there was a signiﬁcant increase with both
the addition of 1% and 2.5% Cell-Ess. (See Figs. 2 and 4.)0.5
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Fig. 3. Increased CHO cell productivity with initial lipid supplement. The addition of Cell-Ess
increase productivity of CHO cells. In this ﬁgure the increase in productivity in SAFC media is
by the ﬁnal VCD cells/l resulting in g/cell and then increase is shown as a percentage. In (B) th
the ﬁnal titer and shown as a percent increase over control.3.2. Viable cell density is not altered by the addition of Cell-Ess ®
An increase in titer can be attributed to either an increase in cell
density, an increase in the number of cells making the same amount
of protein per cell, or increased protein production on a per cell basis.
To better understand if the increase in titer was a result of increased
cell density we investigated the viable cell density (VCD) and viability
of the two different clones treated with Cell-Ess ®. At 0.5% and 1%
additions of Cell-Ess, there was no alteration in VCD. At increasing
amounts of Cell-Ess®, the VCD began to display an effect starting at
the 2.5% concentration in SAFC media. In the Thermo Fisher media the
VCD was also unchanged at 1% Cell-Ess supplementation but with the
addition of 2.5% Cell-Ess there was no effect of the VCD. Adding Cell-
Ess in a speciﬁed ranged of 1%–2.5% did not have any effect on prolifer-
ation or cell viability when added as an initial supplement. Since Cell-
Ess did not increase the cell density the increase in titer was due to in-
creased productivity, and not by more cells making the same or slightly
less protein as in the perfusion model. This is often the case in constant
perfusion systems.
3.3. There is a signiﬁcant increase in the yield per cell using an initial
supplement of Cell-Ess ®
There are multiple ways to measure protein output. One way is to
measure titer where the addition of Cell-Ess increased titer. Another0.5
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as an initial supplement in a short 7 day culture model was analyzed for the ability to
measured by two different methods. In (A) the calculation is the ﬁnal titer in g/l divided
e integral under the VCD curve is calculated and used as the denominator to divide into
AB
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Fig. 4. Addition of lipids does not affect the metabolic proﬁle. Cell-Ess was added at the
indicated levels to SAFC media at the indicated concentrations. Samples were collected
from the associated ﬂasks and frozen until the ﬁnal collection. Samples were thawed
and metabolic analysis for lactate, glucose, glutamate, and ammonia (A, B, C, and D
respectively) was done using a BioProﬁle Nova Flex.
322 A. Elhofy / Computational and Structural Biotechnology Journal 14 (2016) 319–324measure of output is productivity. In this assay we measured if there
was an increase in the amount of productivity on a per cell basis.
Productivity can be measured by one of several different methods. The
most common methodology is to divide the titer from a set time point
and then divide this by the number of cells at that same time point.
The result is an indication of the productivity or amount of protein
secreted on a per cell basis. The addition of Cell-Ess resulted in a signif-
icant increase in the amount of protein secreted per cell. This increase in
productivity was not dependent on cell proliferation as there was no
signiﬁcant increase in total cell growth (129.2 ± 9.0 105 cells day)
when compared to control (145.2 ± 5.3 105 cells day). At 1% addition
of Cell-Ess, there was a greater than 40% increase in productivity. The
addition of lipids increased the amount of total mAb titer by increasing
the productivity of CHO cells. Another more conservative measure of
productivity is to divide the titer of a single time point by the area
under the VCD curve or IVCD. That value describes the production of
the aggregate production over the entire time frame. The addition ofCell-Ess increased productivity of cells using the IVCD method regard-
less of Cell-Ess concentration. These data suggest the addition of lipids
allows CHO cells to more efﬁciently produce protein.
3.4. There is no alteration in the metabolites or salts despite a signiﬁcant
increase in mAb production
Since the addition of lipids increases titer primarily by increasing the
efﬁciency of CHO cells, an experimentwas then conducted to determine
if the increased protein secretion was causing the CHO cells to build up
toxic by- products. Asmentioned in the introduction,metabolic analysis
has been used to optimize CHO cell antibody production. We examined
the entire metabolic proﬁle (Fig. 3) and identiﬁed no signiﬁcant differ-
ences in any of the salts or metabolic by-products. These are common
indicators for potential harmful by-products. Lactate is one factor that
can increase the pH causing cell necrosis. In no fewer than 6 indepen-
dent runs in both models, addition of Cell-Ess as an initial supplement
or as a fed batch supplement did not result in an accumulation of lactate.
In fact after the initial peak, lactate was controlledwhile simultaneously
there was a constant demand for glucose. The addition of lipids did not
feed into the TCA cycle which would result in an increase in lactate as
occurs with the addition of glucose. Since there was an increase in the
amount of protein, there is a potential for the increase the amount of
ammonia, a toxic by-product of additional protein.
3.5. The addition of lipids in a fed batch system results in increased titers
Themost commonmethod to extend culture times and increase titer
is to use a feed during the batch run. Themethod, called fed batch, uses a
variety of feeds to add back nutrients whichwere utilized by the cells in
the bioreactor. There is a way to model the fed batch system in shake
ﬂasks. This study sought to understand - in a system where feeds are
added to an optimized serum free culture condition - if the use of Cell-
Ess as a feed can increase titer or have other beneﬁcial effects, such as
improving cell viability or extending potential run times.
To test this hypothesis we modeled a fed batch system in shake
ﬂasks, with the study variable being feeds of Cell-Ess® at varying
concentrations. Feeds already utilized in these previously optimized
systems were retained to control for the effect of adding Cell-Ess.
There was a beneﬁt of Cell-Ess at all concentrations tested in the fed
batch model unlike the use of the lipid supplement Cell-Ess when
used as a one-time initial supplement. The optimal result was seen
with multiple feedings of Cell-Ess at a concentration of 5%. As seen in
Fig. 5, there were multiple beneﬁts. The ﬁrst is an increase in titer over
the controls. The increase in titer was greater than 30%. The second ob-
servation was the addition of Cell-Ess led to an increase in titer early,
and throughout the run. Finally, the viability improved with the use of
Cell-Ess. The addition of lipids as a feed behaved similarly to when the
lipids were used only as an initial supplement. The titer was signiﬁcant-
ly increased without increasing the cell proliferation. In both models
there was a productivity increase through the use of Cell-Ess.
3.6. A novel liposome can be used in a single use bioreactor
Shake ﬂasks experiments are very useful in modeling behavior and
optimizing conditions prior to entering a bioreactor. The behavior of
the culture in bioreactors can be different than that seen in shake ﬂasks.
We then wanted to determine if the lipid supplement, could be used to
increase titer as shown in the shake ﬂask model Figs. 1 and 5, would be
repeatable in a bioreactor. This experiment involved testing Cell-Ess as
both an initial supplement at 1% and also adding it as a feed at 5% as de-
termined in the shake ﬂask model (Fig. 5). Furthermore, we wanted to
test the lipid supplement in a single use system where lipid use has
been shown to be toxic or not beneﬁcial.
Cell-Esswas tested in a 10 lWave bagwith EVA ﬁlm. Bioreactor runs
done at the 5 L size have been shown to be representative for large-scale
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323A. Elhofy / Computational and Structural Biotechnology Journal 14 (2016) 319–324bioreactor runs up to the 10,000 L scale. The hypothesis would be the
use of Cell-Ess in a SUB would be as efﬁcacious as the run done in the
smaller volume shake ﬂasks.4. Discussion
The use of lipids has been shown to be beneﬁcial but to date there
has not been an optimized method to deliver the lipids into a long
term culture system. Long term culture systems are the standard for
growing and expanding CHO cells for protein production. Many
methods have been employed to determine the optimal media for
each CHO cell and CHO cell clone [7,11,12]. The methods include, but
are not limited to, metabolic analysis [3,11,12], proteomic analysis [11,
13], and network analysis. In this paper we demonstrated a novel lipid
mixture using a proprietary delivery system called Cell-Ess® can deliver
lipids and cholesterol resulting in increased titer by increasing cell
productivity.0 5 10 15 20
0
2000
4000
6000
Wave mAb Titer
Days
To
ta
l y
ie
ld
 (M
G)
Control
Cell Ess
0 5 10 15 20
0
50
100
150
200
Cell Density
Days
Vi
ab
le
 C
el
l D
en
si
ty
 (x
10
5 )
Control
Cell Ess
A
C
Fig. 6. IncreasedmAb titer in single use bioreactor. Cell-Esswas used as an initial supplement an
Ess was added as an initial supplement at 1% as determined in Fig. 1 and then 5% feed was add
percent is shown in B. The VCD and viability rates are shown in A and D respectively.During the process of empirically testing Cell-Ess, several interesting
discoveries were made related to supplementing lipids in a serum free
environment. It was found during the proof of principle experiment,
where Cell-Ess was only added at the beginning of a short protein run,
the amount of lipids might have different effects between different
media When 1% Cell-Ess was added to FortiCHO and SAFC media there
was an equivalent increase in mAb titer. But the FortiCHO SFM support-
ed growth and increased titer with concentration of lipids greater than
1% while with more than 1% Cell-Ess in SAFC media did not sustain
growth, demonstrating there was a different sensitivity based on con-
stituents in the SFM. There was an effect on the proliferation of CHO
cells at 2.5% in the SAFC media but, at 2.5% the FortiCHO did not change
the proliferation and resulted in increased titer. We found this effect
was much broader in the fed batch experiment. In data not shown
here, the number of feeds and the Cell-Ess® concentration per feed var-
ied greatly between media but the result - once optimized - was the
same. Therewas signiﬁcant increase in the titer in bothmodels. It is crit-
ical to optimize the addition of lipids. While we often assume the13 14 15 16 17 18
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324 A. Elhofy / Computational and Structural Biotechnology Journal 14 (2016) 319–324difference in formulations explain why there are different optimization
parameters, it is not clear what speciﬁc ingredient or ingredients are
contributing to this variance.
There is a movement toward single use systems [11,14]. The single
use systems take advantage of a smaller bioreactor and utilize a
constant perfusion to replenish the media and maintain cell health.
The result is increased cell density and increased titer. The increase in
cell density is in the range of 3–5 fold while the increase in titer is
usually 1.5 to 2 fold. From a downstream processing perspective, this
approach increases the amount of cell bioburden and host cell protein
on a per gram puriﬁcation. An increase in productivity (seen in ﬁgure
2) is more desirable as the amount of protein per cell is increased
while the puriﬁcation burden downstream is not affected. The use of
the novel lipid supplement Cell-Ess® increases the productivity on a
per cell basis. Furthermore Cell-Ess functioned equally well in glass
and on a single use ﬁlm.
There are numerous supplements on the market provided by a
variety of companies, but in many cases the supplement is designed to
workwith a speciﬁcmedia formulation. Cell-Ess is designed to be robust
so the results are media agnostic. To date, Cell-Ess has been added to
SAFC, LifeTech (Figs. 1, 5 and 6) and Lonza media (data not shown)
with an increase in titer observed all systems. This was done at differ-
ence sites with different clones and reproduced multiple times with
the same result. As mentioned earlier, the design of an experiment is
crucial to deﬁne the optimal amount of lipid supplement for establish-
ing reproducible results.
The methods used to optimize CHO cell production, such as
metabolic analysis, and proteomic analysis will not predict or demon-
strate the beneﬁt of adding lipids. The output is focused on the TCA
cycle or what proteins are being produced. Here it was demonstrated
that there were no alterations in the metabolic proﬁle even while
there was a signiﬁcant increase in the protein titer. This suggests the
increase in titer does not alter the TCA cycle since there is no increased
lactate. This can mean there is more efﬁcient energy usage which the
cell can then utilize for increased protein production. There have been
reports recently suggesting a metabolic proﬁle in the oxidative state is
conducive to increased titer [3,4]. Another explanation is the lipid's sta-
bilizing effect on the lipid membranes throughout the entire protein
synthesis and secretion pathway.
This study showed the addition of lipids increased mAb titer by
increasingproductivity. This increase did not affect themetabolic proﬁle
of the cell. The next level of investigation will be on protein quality.While preliminary data does exist that is not shown here, the glycolytic
pattern is not signiﬁcantly altered by the addition of Cell-Ess. Further
exploration of the role of adding lipids on protein quality is planned.
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